Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Short Interest Down 17.3% in December

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) was the target of a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 39,800 shares, a drop of 17.3% from the November 30th total of 48,100 shares. Currently, 2.7% of the company’s stock are sold short. Based on an average daily trading volume, of 338,600 shares, the days-to-cover ratio is currently 0.1 days.

Phio Pharmaceuticals Price Performance

Phio Pharmaceuticals stock traded down $0.06 during midday trading on Tuesday, hitting $1.84. 59,242 shares of the company were exchanged, compared to its average volume of 116,962. The company has a market cap of $1.94 million, a PE ratio of -0.17 and a beta of 1.49. Phio Pharmaceuticals has a fifty-two week low of $1.53 and a fifty-two week high of $10.35. The company’s fifty day moving average price is $2.65 and its 200-day moving average price is $3.41.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.